Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

By A. Astrup, S. Rössner, Luc F Van Gaal, A. Rissanen, L. Niskanen, Mazin Al Hakim, J. Madsen, M. Rasmussen, M. Lean. The Lancet, 2009

1,050 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Pharmacology, Surgery

View Paper: https://www.semanticscholar.org/paper/5da92fa329ad0f44a45ed90b7467f2fc21eff89b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. D. J. Drucker
2. J. Meier
3. M. Nauck
4. Jonathan E. Campbell
5. Douglas G. Altman
6. Ralph DeFronzo
7. Josephine M. Egan
8. Wook Kim

In Pharmacology

1. David Moher
2. Douglas G. Altman
3. K. F. Schulz

In Surgery

1. D. J. Drucker
2. David Moher
3. J. Meier
4. M. Nauck
5. Douglas G. Altman
6. Jonathan E. Campbell
7. Matthias Egger
8. Ralph DeFronzo

Citations in the corpus

• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “These agents improve BP and lipids, prevent progression to diabetes during trial periods, and improve glycemic control and lipids in patients with T2D (43-60).”
• CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010, background): “’’[176] ExplanationdData can be analysed in many ways, some of which may not be strictly appropriate in a particular situation.”
• The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (2014, neutral): “Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
• Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. (2018, background): “Drucker, 2013; Drucker and Nauck, 2006), and a single GLP1R agonist, liraglutide, has been approved for the treatment of obesity (Astrup et al., 2009).”
• Pharmacology, physiology, and mechanisms of incretin hormone action. (2013, background): “Hence, although very high GLP-1 responses after GBS promote hyperinsulinemia and hypoglycemia, additional factors beyond GLP-1 likely contribute to sensitization of b cell function and exaggerated insulin release in many subjects after GBS. GLP-1, the Exocrine Pancreas, and Pancreatitis Whether acti”
• CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. (2012, methodology): “We aimed to assess whether data provided evidence of superiority of each liraglutide dose to placebo (primary objective) and to orlistat (secondary objective)’’[176].”